Cassava Starts Second Alzheimer's Study After PT-125 Effects Multiple Biomarkers

 
• By Mandy Jackson

The company formerly known as Pain Therapeutics revealed a 100% response rate in a small Phase IIa study and hopes to confirm the novel drug's effects on all biomarkers tested in Phase IIb.

Neurons and nervous system. 3d render of nerve cells
PTI-125 may help restore normal function of neurons. • Source: Shutterstock

More from Clinical Trials

More from R&D